Clinical Trial Update: A Study of GC1111 in Hunter Syndrom Patients [Phase 3]

View source ↗

Summary

Phase 3 trial of GC1111 in Hunter syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome

Drugs mentioned

• GC1111 (recombinant human iduronate-2-sulfatase)

Snippet

Sponsor: Green Cross Corporation | Conditions: Hunter Syndrome | Phase 3 | Status: COMPLETED